|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000159921 |
Summary for GNE |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000159921 | Gene symbol | GNE |
| Gene name | glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase | |
| HGNC | 23657 | |
| Entrez ID | 10020 | |
| Gene type | protein_coding | |
| Synonyms | GNE|Uae1 | |
| UniProtAcc | Q9Y223 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for GNE |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| GNE | 2.55e+03 | -1.06e+00 | 2.50e-01 | -4.24e+00 | 2.20e-05 | 6.74e-05 | COAD |
| GNE | 5.38e+03 | -2.78e+00 | 3.81e-01 | -7.30e+00 | 2.93e-13 | 8.58e-12 | CHOL |
| Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Top |
Sex-biased somatic mutation for GNE |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for GNE |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LUAD | cg25813936 | chr9:36276882 | CGI:chr9:36258173-36258889 | promoter,gene body | 6.36e-01 | 5.24e-01 | 2.78e+00 | 5.49e-03 | 8.09e-03 | 1.13e-01 |
| KIRP | cg25813936 | chr9:36276882 | CGI:chr9:36258173-36258889 | promoter,gene body | 2.80e-01 | 4.14e-01 | -2.88e+00 | 3.92e-03 | 5.80e-03 | -1.34e-01 |
| CHOL | cg05844977 | chr9:36277403 | CGI:chr9:36258173-36258889 | promoter | 7.40e-01 | 8.64e-01 | -2.06e+00 | 3.90e-02 | 4.26e-02 | -1.24e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg25813936 | chr9:36276882 | CGI:chr9:36258173-36258889 | promoter,gene body | 7.44e-01 | 3.40e-01 | 6.33e+00 | 2.44e-10 | 6.23e-10 | 4.04e-01 |
| BRCA | cg05844977 | chr9:36277403 | CGI:chr9:36258173-36258889 | promoter | 8.07e-01 | 6.00e-01 | 5.76e+00 | 8.48e-09 | 1.91e-08 | 2.07e-01 |
| HNSC | cg25813936 | chr9:36276882 | CGI:chr9:36258173-36258889 | promoter,gene body | 7.53e-01 | 6.07e-01 | 2.61e+00 | 8.98e-03 | 1.76e-02 | 1.46e-01 |
Top |
Exon skipping events with PSI in TCGA for GNE |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for GNE |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for GNE |
| TFs related to GNE. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| LAML | DMRT2 | GNE | 4.96e+00 | 9.91e-01 | 3.85e+00 | 4.98e-03 | Male-biased |
| LAML | HNF1A | GNE | 4.57e+00 | 9.87e-01 | 3.48e+00 | 5.16e-03 | Male-biased |
| LAML | ZNF136 | GNE | 4.41e+00 | 9.80e-01 | 3.49e+00 | 9.73e-03 | Male-biased |
| LAML | ZNF317 | GNE | 4.37e+00 | 9.81e-01 | 3.41e+00 | 8.29e-03 | Male-biased |
| LAML | ZNF418 | GNE | 5.07e+00 | 9.96e-01 | 3.41e+00 | 5.44e-04 | Male-biased |
| LAML | ZNF570 | GNE | 4.38e+00 | 9.86e-01 | 3.22e+00 | 3.91e-03 | Male-biased |
| LAML | ZNF879 | GNE | 4.65e+00 | 9.88e-01 | 3.54e+00 | 4.76e-03 | Male-biased |
| PAAD | ZNF418 | GNE | 4.42e+00 | 9.87e-01 | 3.45e+00 | 5.12e-03 | Male-biased |
| PAAD | ZNF879 | GNE | 4.24e+00 | 9.84e-01 | 3.31e+00 | 5.94e-03 | Male-biased |
| GNE related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for GNE |
| RBPs related to ES in GNE. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| GNE related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs62542711 | chr9:27100859:C:A | - | 0.143273080607414 | 0.00592244716747413 | STAD | Female-baised eQTL |
| rs3861013 | chr9:27103309:A:C | - | 0.143273080607414 | 0.00592244716747413 | STAD | Female-baised eQTL |
| rs3861014 | chr9:27103334:A:G | - | 0.143273080607414 | 0.00592244716747413 | STAD | Female-baised eQTL |
| rs3861015 | chr9:27103416:G:A | - | 0.143273080607414 | 0.00592244716747413 | STAD | Female-baised eQTL |
| rs609392 | chr9:27098665:T:C | - | -0.136663195044674 | 0.00795649820228221 | STAD | Female-baised eQTL |
| rs637957 | chr9:27097543:A:G | - | -0.130953249640737 | 0.0170495822505298 | STAD | Female-baised eQTL |
| rs596427 | chr9:27099246:G:A | - | -0.128838456075695 | 0.0171672629334648 | STAD | Female-baised eQTL |
| rs3120110 | chr9:27100929:G:A | - | -0.128838456075695 | 0.0171672629334648 | STAD | Female-baised eQTL |
| rs615532 | chr9:27104711:G:A | - | -0.128838456075695 | 0.0171672629334648 | STAD | Female-baised eQTL |
| rs62542712 | chr9:27105969:A:G | - | 0.139734802721866 | 0.0173017529983811 | STAD | Female-baised eQTL |
| rs2471827 | chr9:33660197:T:C | - | -0.0756726177189335 | 0.0215436459040873 | LUAD | Female-baised eQTL |
| rs855448 | chr9:33658013:T:A | - | -0.0729159589510779 | 0.0226838808107372 | LUAD | Female-baised eQTL |
| rs10970927 | chr9:32337410:A:G | - | 0.0487817773930194 | 0.0405887012730358 | LUAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs35288758 | chr9:34966811:C:T | - | 0.0892721798632043 | 0.0352527624737927 | LIHC | Male-baised eQTL |
| rs17358651 | chr9:34968034:A:G | - | 0.0874506710338736 | 0.036016837668717 | LIHC | Male-baised eQTL |
| rs68092307 | chr9:34968929:C:G | - | 0.084878913072217 | 0.0493451673418385 | LIHC | Male-baised eQTL |
| rs72715267 | chr9:28777094:C:T | - | 0.107696949385381 | 3.39175164861432e-05 | COAD | Male-baised eQTL |
| rs1590671 | chr9:28768189:C:T | - | -0.0874132278438995 | 0.000282202691212188 | COAD | Male-baised eQTL |
| rs824245 | chr9:28771567:C:T | - | -0.0882095645186386 | 0.000352818072118569 | COAD | Male-baised eQTL |
| rs16913642 | chr9:28772916:C:G | - | 0.0877981385293502 | 0.000570446504453164 | COAD | Male-baised eQTL |
| rs10814752 | chr9:38736900:C:T | - | 0.094761839606635 | 0.00653989211022361 | COAD | Male-baised eQTL |
| rs10974023 | chr9:38753878:A:G | - | 0.0953992256299567 | 0.0101412362909021 | COAD | Male-baised eQTL |
| rs12378527 | chr9:38758272:C:T | - | 0.0929030903907879 | 0.0104048550853664 | COAD | Male-baised eQTL |
| rs12377280 | chr9:38760448:C:G | - | 0.0973929354305783 | 0.0112278553516395 | COAD | Male-baised eQTL |
| rs4978106 | chr9:26793420:T:C | - | -0.0942583959212952 | 0.0170417144215677 | COAD | Male-baised eQTL |
| rs10511777 | chr9:26783465:C:T | - | 0.0936096837523682 | 0.0184077639633626 | COAD | Male-baised eQTL |
| rs10974009 | chr9:38740484:G:A | - | 0.0902680177942886 | 0.0220657638365018 | COAD | Male-baised eQTL |
| rs4978105 | chr9:26790884:T:C | - | 0.0919845192184336 | 0.0223731050401151 | COAD | Male-baised eQTL |
| rs892572 | chr9:26774053:A:G | - | -0.0837523440668599 | 0.0244706205899635 | COAD | Male-baised eQTL |
| rs2383715 | chr9:26775150:A:T | - | -0.0837523440668599 | 0.0244706205899635 | COAD | Male-baised eQTL |
| rs10114963 | chr9:26776235:G:A | - | -0.0837523440668599 | 0.0244706205899635 | COAD | Male-baised eQTL |
| rs7026156 | chr9:26781309:T:C | - | -0.0837523440668599 | 0.0244706205899635 | COAD | Male-baised eQTL |
| rs7041493 | chr9:26781924:C:T | - | -0.0837523440668599 | 0.0244706205899635 | COAD | Male-baised eQTL |
| rs573787 | chr9:27178323:G:C | - | -0.0487226615815308 | 0.025700438724977 | COAD | Male-baised eQTL |
| rs1889900 | chr9:26789977:C:A | - | -0.0832840415252275 | 0.0257965013758877 | COAD | Male-baised eQTL |
| rs2225811 | chr9:26784269:T:G | - | -0.0830115792079098 | 0.0269713375518559 | COAD | Male-baised eQTL |
| rs10757629 | chr9:26784196:A:T | - | -0.0798103429322621 | 0.0345671822612409 | COAD | Male-baised eQTL |
| rs10967588 | chr9:26898825:A:T | - | 0.0828591678385609 | 0.0366538664001539 | COAD | Male-baised eQTL |
| rs4128122 | chr9:38742057:A:G | - | 0.0886408088763938 | 0.0382096313085523 | COAD | Male-baised eQTL |
| rs10812460 | chr9:26773261:A:T | - | -0.0719929351368683 | 0.0412035715140384 | COAD | Male-baised eQTL |
| rs1336334 | chr9:26790797:G:C | - | -0.076324985519863 | 0.0475595054787033 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000159921 |
| CpG Site: cg25813936 | |
| Position to Gene: gene,promoter | |
| Male Effect: -0.158450663913868 | |
| Female Effect: - |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg25813936 | chr9:36276882 | gene,promoter | -0.158450663913868 | 2.10853081103454e-05 | -0.36270328452290185 | 5.447067200805351e-08 | LUAD |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of GNE |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000159921 | GNE | C0238190 | Inclusion Body Myositis (disorder) | 1 | CTD_human |
| ENSG00000159921 | GNE | C0342853 | Sialuria | 1 | CTD_human |
| ENSG00000159921 | GNE | C0751713 | Inclusion Body Myopathy, Sporadic | 1 | CTD_human |
| ENSG00000159921 | GNE | C1096902 | Infantile Sialic Acid Storage Disease | 1 | CTD_human |
| ENSG00000159921 | GNE | C1096903 | Sialic Acid Storage Disease, Finnish Type (disorder) | 1 | CTD_human |
| ENSG00000159921 | GNE | C1833373 | Inclusion Body Myopathy, Autosomal Recessive | 1 | CTD_human |
| ENSG00000159921 | GNE | C1853926 | NONAKA MYOPATHY | 1 | CTD_human |
